Skip to content Skip to footer
Subscribe Now
Travere Therapeutics
NEWS

Travere Therapeutics Reports FDA Full Approval of Filspari for Proteinuria Reduction in FSGS

Shots: The US FDA has granted full approval to Filspari (sparsentan) to reduce proteinuria in pts (≥8yrs.) with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome Approval was based on the global P-III (DUPLEX) trial assessing Filspari vs irbesartan in 371 pts (8–75 yrs.) with biopsy-proven or genetic FSGS, following a 2wk. washout, with dose titration…
April 14, 2026

Read more

Pfizer New
NEWS

Pfizer’s Braftovi Regimen Receives US FDA Full Approval for Metastatic Colorectal Cancer

Shots: The US FDA has granted full approval to Braftovi + cetuximab & fluorouracil-based CT for the treatment of adults with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation Approval was backed by the P-III (BREAKWATER) study assessing Braftovi (300mg, PO, QD) in pts, randomized to Braftovi + cetuximab (n=158), Braftovi + cetuximab + mFOLFOX6 (n=236),…
February 25, 2026

Read more

NEWS

PRN Pharmacal Receives the Full US FDA Approval for KBroVet to Control Seizures in Dogs with Idiopathic Epilepsy

Shots: The US FDA has granted full approval to KBroVet (potassium bromide chewable tablets) under NADA for the control of seizures associated with idiopathic epilepsy in dogs KBroVet offers benefits for dogs, incl. renal excretion via glomerular filtration for those with liver issues, once-daily dosing, & flavored, chewable tablets formulated specifically for dogs KBroVet has a…
February 13, 2026

Read more